Paul Capital banks on Skyepharma

The capital will be used to fund clinical trials of SkyePharma’s new drug. So long as the drug succeeds in these trials and is passed by regulators, the private equity company will take a share of future sales.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this